By Michael Gerber, MD, HMD

Annie Brandt, founder of the International Organization of Integrative Cancer Physicians (IOICP), the Best Answer for Cancer Foundation, and 18-year survivor of breast cancer, brought a great selection of speakers and exhibitors for her 16th annual conference in Orlando, Florida, on May 17-19, 2018. A summary of Day 1 appeared in the August-September 2018 issue and Day 2 appeared in December 2018. This article covers Day 3.

Care and Feeding of Mitochondria

Dr. Nalini Chilkov, LAc, OMD, the founder of the American Institute of Integrative Oncology and author of 32 Ways to Outsmart Cancer:  How to Create a Body Where Cancer Cannot Thrive, instructs us that there is more to mitochondrial function and cancer than the Warburg Effect and the shift from oxidative phosphorylation to aerobic glycolysis.  Mitochondria are crucial cell monitoring sentinels governing cell death through autophagy, mitophagy, and apoptosis.

The overexpression of the Bcl-gene is associated with cancer cell survival and inhibition of apoptosis.  The pro-apoptotic Bcl-2 family members Bax and Bak are recruited to mediate mitochondrial outer membrane permeabilization (MOMP), resulting in pore formation and cytochrome c release from mitochondria into the cytosol to activate caspases, the executors of programmed cell death.  Tumor cells escape apoptosis by downregulating pro-apoptotic Bcl-2 genes and/or upregulating anti-apoptotic Bcl-2 genes.

Phytochemicals in food and spices that promote normal apoptosis by inhibition of Bcl-2 include the following: allicillin, apigenin, carnosol, sulforaphanes, I3C, curcumin, gingerol, chrysin, EGCG, resveratrol, pterostilbene, quercetin, genistein, capsaicin and gallic acid. These compounds are found in garlic, parsley, celery, broccoli, kale, turmeric, ginger, rosemary, oregano, cayenne, grapes, red onions, red apples, pomegranate, red berries, blackberries, blueberries, green tea, soybeans, Botanicals that promote normal apoptosis by inhibition of Bcl-2 include the following:  Curcuma longa, Panax ginseng, Polygonum cuspidatum, Rabdosia rubescens, Camelia sinensis, Magnolia cortex, Andrographis paniculata, Taxus brevifolia, Scutellaria baicensis, Salvia miltiorrhiza, Dioscorea spp,  Ganoderma lucidum, Pleurotus pulmonarius, Inonotus obliquus, Rosmarinus officinalis, Tanacetum parthenium, Tababueia spp, Zingiber off., Withania somnifera, Berberis vulgaris, Coptis chinensis, and Viscum album.

Nutraceutical supplements that promote normal apoptosis by inhibition of Bcl-2 include the following:  curcumin, EGCG, resveratrol, pterostilbene, Honokiol, indole-3-carbinol, quercetin, berberine, Tanshinone, reishi mushroom, chaga mushroom, and chrysin, all in 500-1000 mg tid dosing.

Tumor suppressor gene p53, guardian of the genome, induces apoptosis in response to stress. Upon activation, p53 leads to cell-cycle arrest and promotes DNA repair or induces apoptosis.  Loss of wild-type p53 function is often associated with aggressive tumor growth, poor prognosis, and resistance to chemotherapy.  Restoration of p53 function in mice suffering from lymphomas or sarcomas has been shown to induce tumor regression.

More than 50 percent of human tumors contain a mutation or deletion of the p53 gene.  Natural compounds that normalize p53 function are very similar to the Bcl-2 herbs and include 5-methyl-tetrahydrofolate, tocotrienols and vitamin E succinate.

Hexokinase II derived cell penetrating peptide targets mitochondria and triggers apoptosis in cancer cells. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro.   Resveratrol also induced apoptosis and inhibited tumor growth in mice.

MicroRNA (miRNA) are a class of single-stranded non-coding RNA molecules, approximately 22 nucleotides that play crucial roles in gene expression.  The same phytochemicals upregulate these miRNAs, which help regulate apoptosis in cancer cells.

Dr. Chikov’s presentation was heavily documented and is available from her study guide, lecture summary notes and lecture slides.   Download at www.aiiore.com/ioicp2018.  Email: drchilkov@aiiore.com.

Creating Genomic Stability in Patients with Cancer by Disabling ENOX2 Proteins and Restoring Microbiota Balance

Mitchell J. Ghen, DO, PhD, discussed the ENOX family of cell surface proteins, which is very complex and has far reaching influences upon certain areas of plant and animal biochemistry. These include being responsible for setting the length of periods of activity and inactivity within cells in the body, acting as an internal biological clock.  Over 250 peer-reviewed papers have been published on the ENOX proteins.  (Morré &Morré (2013) ECTO-NOX Proteins: Growth, Cancer, and Aging).

Why ENOX2?  Research has detected ENOX2 proteins four to ten years before development of clinical symptoms. It is cancer specific, elevated early, and useful for screening early intervention.  (Morré et al. (2016) Clin. Proteom. 13:2).  ENOX2 comes from thiol interchange/cell enlargement in cancer cell membranes to promote unregulated growth. EGCg is a polyphenol that binds to ENOX2 receptor sites, disables them, and is synergistic with the vanilloid component of a specific chili pepper. Ghen gives a summary of outpatient infusion protocol for Capsol-T/ElimENOX2.

Dr. Ghen also reviewed the role of bacteria causing toxic carcinogenic metabolites, increased inflammation, antigen driven lymphoproliferation, and induction of hormones that increase epithelial proliferation. Microbial waste products and mycotoxins weaken the immune system and are causative in prostate cancer, chronic prostatitis, cervical cancer-chlamydia, (HPV), PAL (pyothorax associated lymphoma), Hodgkin’s B cell lymphoma, leukemia, and MALT lymphomas. EBV is found in 70-85% of the PAL tumors in Asia.  Ghen lists over 300 pathogens capable of enhancing or relating to oncogenesis, including H. pylori, Chlamydophilia psittaci, Borrelia burgdorferi, and mycoplasma.

Treatment with silver hydrosol products has two key advantages:  they are broad-spectrum antibiotics and are not yet associated with drug resistance.  (Lansdown AB, “Silver. I:  Its Antibacterial Properties and Mechanism of Action.”  J Wound Care. 2002 Apr 11:125-30) Size makes a difference; at 23 parts per million (ppm), there may be over 300,000,000 particles of active silver in every drop of pharmaceutical-grade silver. Silver improves or stimulates the rate of bone marrow WBC production. Indirect mechanisms of action include an increased production of reactive oxygen species, and it induces or catalyzes increased WBC production of myeloperoxidase. Silver has an excellent safety record in these nanosized particles.

Without removal of microbes, the cancer can return.  He emphasizes no raw meat, no sushi and reduce sugar.  Microbe-killing foods and spices include onion, garlic, allspice, oregano, thyme, tarragon, curcumin, clove, bay leaf, and cayenne pepper.

In summary, cancer treatment aims to block ENOX2 proteins, restore microbiome, decrease inflammation, decrease free radicals, increase nutrition, decrease blood viscosity, disrupt reproductive cycle, improve healthy stem cell function and immune response, and institute positive lifestyle changes.

Contact Mitchell Ghen, DO, PhD, in Boca Raton, Florida, Email: ghenm@mac.com.

The Unmet Need

Travis Christofferson has degrees in molecular biology, material engineering, and science.  He is the author of the best-selling Tripping Over the Truth:  How the Metabolic Theory of Cancer is Overturning One of Medicine’s Most Entrenched Paradigms.  He is the founder of the Foundation for Metabolic Cancer Therapies, and the CEO of Care Oncology USA. He spoke about off label uses for common drugs in cancer therapy

Christofferson commences with the quote from Lewis Cantley, the director of the Cancer Center at Weill Cornell Medicine: “Metformin may have already saved more people from cancer deaths than any drug in history.” Nobel laureate James Watson (of DNA-structure fame), who takes metformin off-label for cancer prevention, once suggested that the drug appeared to be “our only real clue into the business” of fighting the disease.

Metformin may have broad utility in cancer treatment.  Researchers at MD Anderson found that among 2,529 women with early-stage breast cancer, the pathological complete response rate after chemotherapy was higher by 24% in diabetic patients who had received metformin than in diabetic patients who had not received metformin (8%) and in nondiabetic patients (16%).  In the second study, a group in Department of Gastrointestinal Medical Oncology found that among 255 diabetic patients, the risk of developing pancreatic cancer was 62% lower in those who received metformin than in those who did not.  Studies at the University of Pennsylvania reported dramatic improvement in local recurrence in 16 lung cancer patients who received chemoradiation while taking metformin. A study followed 87,344 men diagnosed with prostate cancer between 2000 and 2008.  The median overall survival for non-diabetic (not taking metformin), diabetics on metformin, and diabetics not on metformin was 7.1, 9.1, and 7.4 years, respectively.  The study concluded that both overall survival and cancer-specific survival was significantly prolonged among the diabetics on metformin.

Statins have also been associated with cancer risk reductions. Several observational studies and meta-analyses have shown reduction in risk of multiple cancers with statin therapy.  A recent Danish study showed a 15% reduction in all-cause and cancer specific mortality in statin users as compared to non-users.  Improved survival with statin exposure was seen in 13/17 cancer subtypes, including the four most common cancers; lung, prostate, colorectal and breast.

Statins could reduce risk of breast cancer death by 38%, research shows.  Overall statin use was associated with a 27% reduction in both cancer-specific and overall mortality.  However, those who took the same drugs for more than four years did not appear to show the same protective association, with only a 16% reduction in cancer-specific death, or death from all other causes.  A VA retrospective case-control study of 483,733 patients from 1998 to 2004 showed a reduction of lung cancer by 55%.  Statins appear to be protective against the development of lung cancer.

Pravastatin seems to be more effective than Simvastatin on the growth of tumor cells from different organ sites. Pravastatin increased survival time in unresectable hepatocellular carcinoma.  Median survival was 18 months in the pravastatin group versus 9 months in controls.  (Kawata S. et al.  Br J Cancer. 2001 Apr 6;84(7):886-91).

Statins (HMG-CoA reductase inhibitors) are well know cholesterol-depleting agents.  It has been shown the statins may inhibit the cell cycle by influencing both expression and activity of proteins involved in cell-cycle progression such as cyclins and cyclin dependent kinases.  By inhibition of the synthesis of cholesterol, statins may destabilize the cell membrane. The following study reviews several other proposed mechanisms for anti-cancer activity:  Matusewicz, et al. The effect of statins on cancer cells – a review. Tumor Biol. 2015 Jul; 36 (7): 4889-904.

The combined metformin-statin program reduced hepatitis B risk for developing cancers nearly in half.

Targeting cancer stem cells with antibiotics is another new treatment modality. Antibiotics that target mitochondria effectively eradicate cancer stem cells across multiple tumor types, treating cancer like an infectious disease. New analysis shows that four to five different classes of FDA approved drugs can be used to eradicate cancer stem cells across 12 different cancer cell lines, including breast, DCIS, ovarian, prostate, lung, pancreatic, melanoma, and glioblastoma.  These five classes of mitochondrially targeted antibiotics include the erythromycins, the tetracyclines, the glyclycyclines, as well as the anti-parasitic drug chloramphenicol.  Data were presented for one antibiotic in each drug class:  azithromycin, doxycycline, tigecycline, pyrvinium pamoate, as well as chloramphenicol. Mebendazole and a non-steroidal anti-inflammatory combined to reduce tumor initiation in a colon cancer preclinical model  (Williamson T, et al. Oncotarget. 2016 Oct 18;7(42):68571-68584).

An oncology clinic from the UK developed COC ProtocolTM, using metformin, atorvastatin, doxycycline, and mebendazole. Using individualized doses of the above medications gave improved results in a METRICS trial on glioblastoma. Two-year overall survival was 55% in the standard of care + COC protocolTM versus a 28.7% survival in the standard of care alone group.  Advantages to the proprietary off label protocol include the following:  decades of clinical use establishing safety, targets ubiquitous metabolic dysregulation, provides critical need for adjunctive therapy, provides a treatment option when no other exists or has been exhausted and provides a treatment option to prevent recurrence.

“Even James Watson, one of the fathers of molecular biology, is convinced that targeting metabolism is a more promising avenue in current cancer research than gene centered approaches.  At his office at the Cold Spring Harbor Laboratory in Long Island, Watson, 88, sat beneath one of the original sketches of the DNA molecule and told me that locating the genes that cause cancer has been ‘remarkably unhelpful’.   If he were going into cancer research today, Watson said, he would study biochemistry rather than molecular biology.”  (An Old Idea Revived: Starve Cancer to Death. New York Times, 2016)

Cannabinoids and Terpenoids

Dr. Steve Ottersberg is the founder of Green Lab Solutions Company (Durango, Colorado), operating as Colorado’s 11th certified cannabis testing laboratory.  He has a BS in biochemistry and an MS in biochemistry from Arizona State University and has an honorary ND from Southwest College of Naturopathic Medicine. He shared his knowledge of human genetic testing in medicine to an audience of physicians, expanding understanding of the biochemical connections between polymorphisms of key enzymes associated with multiple disease states.

Cannabinoid Receptors

Endocannabinoids are fatty acid esters that act upon cannabinoid receptors. Terpenes include isoprenes, monoterpenes and sesquiterpenes.  All are parts of cannabis in varying strains.

Alpha-Pinene, found in cedarwood, pine, rosemary oil and Boswellia serrata, is anti-inflammatory, broncho-dilating, stimulating, antimicrobial, and nootropic. It is also found in cannabis.

Camphene is found in camphor, mothballs, Zingiber officinale, Rosmarinus officinalis, and Salvia officinalis.  It is analgesic, anti-inflammatory, sedative and antimicrobial.

Beta-Pinene is found in pine, polish, wood and also in parsley and nutmeg.  It is analgesic, anti-inflammatory, stimulating, and nootropic.

Beta-Myrcene, found in Balsamic, fruit, geranium herb, cardamom, Piper nigrum, and Boswellia sacra, is anti-nociceptive, anti-inflammatory, sedative, euphoric, and anti-mutagenic.

Delta-3-Carene is found in pine, Piper nigrum, Thymus vulgaris, and star anise.  It is anti-inflammatory, sedative and nootropic.

D-Limonene is found in citrus, mint, Vitex agnus-castus, Citrus limon, and celery.  It is anti-tumor, anti-inflammatory, a cannabinoid agonist, antidepressant, stimulant, calming agent, nootropic and euphoric.

Ottersberg made a big point that limonene, (lemon peel in hot water), will counteract cannabis overdose!!!!

This reviewer has confirmed the efficacy of this treatment very recently in a patient who accidently overconsumed an edible cannabis product.  He was quite focused, non-communicative, not moving, and apparently holding on to his consciousness.

After sipping lemon peel in hot water, he immediately started to come back into regular consciousness and was able to walk. A peppermint oil drop, which is a stimulant and demulcent, licked from the back of his hand, was also very helpful. His nausea was helped by applying pressure to the acupuncture point Pericardium 6, four fingerbreadths above the inner wrist creases.  Bringing him back into his body was helped by apply acupressure to Liver 3, at the junction of the large toe and second toe joints bilaterally.

I have seen several cases of cannabis overdose and have employed Governor Vessel 26, one-third of the distance between the nose and the upper lip in the midline, if consciousness is deteriorating.  An acupuncture needle insertion is ideal, but a ball point pen stimulating the point, a hat pin, a sharp finger nail, and on one occasion an umbrella from a tropical drink helped bring a patient back from waning consciousness. Death or debility from overdose is highly unlikely, but the experience of the event may be disconcerting.

D-Limonene and its metabolites, perillic acid, dihydroperillic acid, uroterpenol and limonene 1, 2-diol, may inhibit tumor growth via inhibition of p21-dependent signaling and apoptosis resulting from induction of the transforming growth factor beta-signaling pathway.  D-limonene induces apoptosis via the mitochondrial death pathway and suppression of the PL3K/Akt pathway in human colon cancer cells. Animal studies show activity of D-limonene against pancreatic, stomach, colon, skin, and liver cancers. Ottersberg presented 22 citations to support these data.

Fifteen more terpenoids were presented with therapeutic potentials similar to the above terpenoids in their effects.

In addition to terpenes, Ottersberg discussed cannabinoids. Cannabinoids, represented by Delta 9 Tetrahydrocannabinol are analgesic, anti-inflammatory, and antiemetic. Cannabidiol is anxiolytic, analgesic, antipsychotic, anti-inflammatory and antispasmodic. Cannabigerol is an appetite stimulant and neuroprotective. Delta9-Tetrahydrocannabinol decreases turnover of brain histamine. (Oishi R et al. J Pharmacol Exp Ther. 1985 Feb; 232(2):513-8.)

Ottersberg included a very large bibliography for his presentation.

Immunotherapy

Antonio Jimenez, MD, ND, CNC, Chief Medical Officer, Hope4Cancer Treatment Centers in Baja California, and Cancun, Mexico, spoke about what makes cancers difficult to treat with conventional therapies: tumor heterogeneity, genetic variability from tumor formation to metastasis, and the difficulty of targeting diverse metabolic pathways.

He utilizes therapies that target specific cancer-related molecular receptors/antigens, hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, monoclonal antibodies that deliver chemotherapy, cancer vaccines, gene therapy, and immunotherapies.

If the immune system has it all figured out, why do we get cancer? Cancer cells are survivors and masters at immune evasion and may not present recognizable antigens. Pluripotent cancer stem cells display virtually no antigens on their surfaces.   Inflammation triggers the expression of protective antigens on cancer cells, e.g. PD-L1, that suppress T cell activity.  Tumors subvert macrophages and other immune cells to create its own toxic, self-defense system in the tumor micro-environment.

There are several types of immunotherapy drugs that target cancer cells and tumors:

·       Monoclonal antibodies are engineered to target specific antigens and may be used to deliver chemotherapies to targeted cancers cells.  The first, Rituximab, was approved in 1997 and targets CD20 on malignant B lymphocytes.

·       Cytokines are substances released by T cells to kill cancer cells.  The first cytokine IFN-a was approved for the treatment of cancer in 1986.

·       Autologous cell therapy/cancer vaccines are immature antigens presenting cells extracted from the body, which are engineered to contain a cancer-specific antigen and are reintroduced as a vaccine.  The first vaccine: Sipuleucel-T was approved in 2010 for prostate cancer.

·       Oncolytic virotherapies uses viruses to locate, infect, and kill cancer cells.  The first genetically unmodified oncolytic virotherapy, Riga virus, was approved in 2004; Amgen’s T-VEC was the first engineered oncolytic virotherapy.

·       Immune checkpoint inhibitors (ICIs) are antibodies engineered to bind to ligands on cancer cells or block receptors on T cells that inhibit their ability to kill cancer cells.  The first approvals:  Ipilimumab (Yervoy), a CELA-4 inhibitor: Nivolumab (Opdivo), a PD1 inhibitor.

·       Adoptive T cell transfer:  TCR and Car T cell therapies are personalized therapies based on modifying T cells from the patient. They involve amplification of T cells in the laboratory.  Pre-treatment of patients with chemotherapy to kill immune system cells and the transfer of the CAR/TCR containing T cells to the patient is the treatment paradigm.

Jimenez raises concerns surrounding effectiveness and safety of the new immunotherapies.  Serious adverse events are common and include autoimmune and inflammatory reactions, endocrinopathies, dermatitis, colitis, hepatitis, immune evasion and resistance. Currently, about 70% of patients cannot be prescribed immunotherapies at all.  Hyperactivation of T cells cause unexpected organ damage, severe neurotoxicity, lowered blood pressure, and patient death from treatments.  Cytokine storms from overactivation of T cells cause labored breathing, rapid pulse, high fevers, decreased blood flow to organs and coma. Pre-administration of chemotherapy/radiation is needed, resulting in the killing of the existing immune system to clear the path for engineered T cells. They are also poorly penetrating into solid tumors.

Immune checkpoint inhibitors (ICIs) have a similar panoply of side effects.  ICI immunotherapy drugs will not benefit over 90% of patients of cancer patients.

Jimenez advocates 7 Key Principles of Cancer TherapyTM. Non-toxic cancer therapies, immune modulation, oxygenation, full spectrum nutrition, restoration of the microbiome, detoxification and emotion and spiritual healing are the foundation of his therapy program. He uses Sono-Photo Dynamic Therapy, Interstitial PDT Laser Application, GcMAF, mistletoe therapy, and oncolytic virotherapy.

GcMAF: Mechanism of Action Hypothesis

Mistletoe releases cytokine transmitters (e.g.IL-1, IL-6, TNF-a, IFN-g, GM-CSF).  Immunomodulatory effects include increased amount and activity of many types of immune cells (e.g. dendritic cells, B-cells and T-cells). It causes indirect immune-mediated tumor inhibition and lowers susceptibility to infections.

Oncolytic virotherapy is classified as an immunotherapeutic agent in Latvia because of its specific ability to cause immune-mediated damage to tumor cells. In peripheral blood, cytotoxic CD38+, CD95+, and activated T cells are elevated along with apoptosis receptors.  Repeated courses of oncolytic virotherapy taken by a patient are designed to encourage a sustained immune system response that in the long-term favors tumor rejection. It has been shown in clinical situations that repeated application of oncolytic virotherapy results in the gradual regression of lymph node micro metastases and subcutaneous metastasis in melanoma patients.

Also, hyperthermia (local and full body), autologous antigen receptor specific oncogenic targeted acquisition (AARSOTA), vitamin C IV therapy, nutrition therapy, ATP-1 personalized supplementation and nutrients, including vitamin D and propolis, lymphatic massages, and hormonal optimization are routine therapies in his clinics.

Beat Cancer and Win the Fight by How You Live

Leigh Erin Connealy, MD, graduated from the Chicago Medical School and received post-graduate training at the Harbor/UCLA Medical Center in Los Angeles.  She founded The Center for New Medicine in Irvine, California, and wrote The Cancer Revolution, many articles, and appears on Dr. Detective, airing on KDOC, Roku, and Apple ETV.  Her newsletter can be found at NewportNaturalHealth.com. She regards healing as caring for the whole person—body, soul and spirit—sharing the healing power of faith, hope and love while advancing science and medicine to put an end to cancer one person at a time.

Cancer is a multi-factorial disease.  One particularity of cancer cells is their refusal to die.  They escape apoptosis because of the failure of tumor suppressor genes that control cell cycle apoptosis.  P53 is the guardian of the genome and mutation occurs in more than 50% of cancer.

The British Medical Journal of October 4, 2017, said that there was no clear evidence that most cancer drugs extend or improve life. Dr. Connealy states that the majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients.

Cancer is the number one killer of people, ages 1 to 85. In 1900, one person out of 100 developed cancer; today we have reached one person out of three. Very soon we will be one out of every two. Currently 1,647 die from cancer every day or 601,000 cases in the US alone annually.  There are 14 million new cases per year with 8.2 million deaths every year.  There has been no significant increase in survival rate over the past 35 years.  Resistance to chemotherapeutic drugs is considered the greatest obstacle to the successful management of cancer patients.

Dr Connealy cites the lack of digestive enzymes, stress, over-acidic environment and diet, toxins, bugs, biological factors, and DNA methylation irregularities as primary causes of cancer.

Toxins include rradiated food, additives, mercury toxicity, dental factors, electromagnetic fields, sick building syndrome, ionizing radiation nuclear radiation, pesticides, industrial toxins, heavy metals, xenoestrogens, phthalates, polluted water, chlorinated water, fluoridated water, tobacco and smoking, immunosuppressive drugs and all drugs increase cancer risk.

Bugs, such as bacteria, fungus, molds, mildews, and candida, parasites and viruses, need to be addressed to reduce the infectious load on the immune system.

Emotional Stress. Good stress increases B-endorphins, enhances immune system function, and increases immune response.  Bad stress decreases B-endorphins and decreases immune system function, causing depression and fatigue. These emotions increase inflammation in the body and enhance development of illness and infection.

Biological Factors. Dietary and nutritional deficiencies, toxic emotions, depressed thyroid, gluten allergy, heavy metal toxins, intestinal toxicity, hormone therapies, (birth control, synthetic estrogens, hormone blockades), blocked detoxification (bad circulation, scars, calluses), cellular oxygen deficiency (acidity, lack of exercise, pollution, cellular terrain), free radicals and vaccines block P53 activation.

P53 mutation is associated with every step of tumor growth, metastases, and invasion. This mutation is associated with aggressive cancer, angiogenesis, resistance of cancer cells to chemotherapy/radiation, breast, glioma, pancreatic, and colon cancers.

Root Canals. Over 40,0000,000 Americans receive root canals every year. Ninety-eight percent of breast cancer patients have had one or more root canals. Root-canaled tooth bacteria are extremely dangerous and release toxins that can travel in the blood stream and cause cancer, stroke, and heart attacks, among many other diseases.

Causes of P53 Mutation

Dr. Connealy discussed cancer profile tests. She recommends HCG blood and urine tests, PHI (autocrine mobility factor) CEA, carcinoembryonic antigen, GGTP, very sensitive liver enzyme, TSH (basic thyroid screen) I also recommend free T3 and free T4 , and DHEA-S, the adrenal anti-stress, pro-immunity, longevity hormone.  Dr Connealy likes circulating tumor cells blood test, RGCC, serum ferritin, and CRP.

Thermography should be considered as an alternative to mammograms. It measures infrared heat radiating from the body and can detect 86% of non-palpable breast cancers up to ten years before a cancerous tumor can be found. It can differentiate cancer from other breast diseases and is completely safe, non-contact, pain- and radiation-free.

Ivy Gene test is a blood test for the presence of cancer and quantification of cancer presence and uses advanced DNA sequencing methods to detect DNA methylation patterns of cell free DNA in blood.  Unlike many genetic tests that use DNA to determine the propensity or possibility of developing cancer over time, the Ivy Gene test identifies DNA methylation pattern consistent with actual disease presence at the time of testing.

Cancer therapies and treatments include the following: SOT/RGCC, dendritic vaccination, insulin potentiation therapy (IPT), low-dose chemotherapy after insulin pretreatment, high-dose vitamin C with K2, hyperbaric oxygen, nanovated bath therapies, EVOX emotion therapy to resolve negative emotions via frequencies sent through a medical device hand cradle, targeted nutritional supplements, PEMF, far infrared sauna therapy, total body ozone, cryotherapy, hyperthermia, light beam with ozone, IV vitamin C, Salicinium, Poly MVA, artemisinin, DCA, sodium bicarbonate, mistletoe, dendritic cell vaccine, curcumin and other detox therapies such as coffee enemas which reduces toxicity by 700%.  Resveratrol activates NF-kB.  In addition, CoQ10, omega 3s, melatonin, curcumin, genistein, lycopene, poly mannose extract from aloe vera, modified citrus pectin, fucoidan, quercetin, selenium, Boswellia, green tea (ECGC) and D3.

Cryoablation can be used in place of open surgery to ablate tumors if the tumor, because of its location, would have been challenging to reach surgically and if radiation would have caused considerable collateral damage to surrounding organs. Cryosurgery can be used to treat both external and internal tumors. To treat internal tumors, argon gas is delivered into the tumor through a cryoprobe. Ultrasound or MRI is used to guide the probe’s placement. A ball of ice forms, freezing nearby cells. Cells die as they thaw. Sometimes cryotherapy must be combined with chemotherapy.

Targeted low-dose therapy was developed in the 1930s and has been used in cancer therapy since 1946.  It uses insulin followed by glucose to deliver drugs more efficiently and to make them work in smaller doses with reduced or no side effects. It is gentler, safer (1/10 dose), more effective, less expensive with no surgery or radiation and usually no side effects.

Gc Protein-derived Macrophage Activating Factor (GcMAF) acts as a director of the immune system and instructs macrophages to kill malignancies.  Nagalase is an extracellular matrix-degrading enzyme that is secreted by cancerous cells in the process of tumor invasion.  Nagalase activity is directly proportional to viable tumor burden.  The nagalase test measures the activity of alpha-acetylgalactosaminidase in the blood.  Patients should have their blood tested before treatment, after three weeks of treatment, and again following eight weeks of treatment.  There should be a significant drop in nagalase level (a level below .65 indicates the body will be able to begin to produce its own GcMAF).

Vitamin C IV. Dr. Mark Levine led a team of researchers to analyze the cancer-killing effect of high-dose vitamin C treatment.  They discovered that by utilizing high dose and rapid intravenous infusion of vitamin C, large concentrations of vitamin C can be reached in the extracellular space.  There, vitamin C reacts spontaneously with the molecular oxygen within tumors and generates large amounts of hydrogen peroxide, which is lethal to tumor cells.  Tumor cells produce small amounts of protective catalase.  Vitamin C given in high doses intravenously to a group of human subjects found that it effectively eradicated cancer cells while leaving healthy cells intact.  (University of Kansas). High-dose IV vitamin C can stop new blood vessels from growing in cancer by creating an inhospitable, highly oxygenated environment.

Total body ozone therapy. Ozone has been used in Germany since 1950 and is considered one of the main treatments for a variety of diseases.  It is a potent regulator of the immune system, increases oxygenation to the tissues, improves circulation, increases antioxidant production, and is anti-microbial.  Being a powerful stimulant to the mitochondria it is helpful in detoxing ETOH, improves microcirculation and is beneficial for diabetic patients.

IV Treatments. Curcumin, silymarin, resveratrol and mistletoe strongly effect natural killer cells which help promote tumor cell death and reduce cancer recurrence. Salicinium is a natural plant-based extract. Amygdalin (also known as Laetrile or Vitamin B17) is found in raw nuts and the pits of many fruits, particularly apricot kernels and can be of benefit. Artesunate, from artemisinin (wormwood) has a similar effect to gemcitabine and causes significant tumor regression in human pancreatic cancer cells.  Hydrogen peroxide, very diluted has a similar activity to high-dose IV vitamin C.  Glycyrrhizin is derived from the licorice plant and has therapeutic potential against prostate cancer say researchers from the University of Illinois.

Glutathione is one of the body’s chief antioxidants. Cancer patients have lower levels of this powerful antioxidant, especially those using conventional therapies (chemotherapy, radiation and surgery) which can lead to cell damage and negative health effects.

EDTA Chelation Therapy. Ethylenediaminetetraacetic acid (EDTA) is a synthetic amino acid related to vinegar. EDTA is taken intravenously (Also topically, orally and rectally) and removes heavy metals. A study published in the Journal of Advancement in Medicine found a 90% reduction in mortality in 59 cancer patients during the 18 years follow-up when treated with EDTA. Reviewer’s note: It also removes the toxicity of platinum after chemotherapy with cisplatin or carboplatin.

Dendritic Cell Therapy is an immune therapy that harnesses the body’s own immune system to fight cancer.  The dendritic cell (DC) is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells in the effector arm of the immune system.

The creation of an individualized DC vaccine involves the harvesting of patient’s own blood cells to be processed in a lab to isolate cancer cells and identify the most frequently expressed “epitope” (protein) on the surface of cancer cells and imprint dendritic cells with that “epitope.”   The new DC population is augmented (increased in numbers) in preparation to be introduced back into the patient’s body.  The goal of DC is to educate T and B cells to identify the cancer cells and mark them for destruction for macrophage clean-up.  If the vaccine “takes” it will give long term immunity against cancer cells.

Stage IV breast cancer patient treatments include the following: EVOX, emotional evaluation, nutritional consult, hemosonic infrared sauna daily, hyperbaric treatments (three times weekly), nano bath (twice weekly), LBG (light beam generator to stimulate lymph flow, three times weekly), PEMF daily, IV vitamin C, Vitality C (1 tsp twice daily), pancreatic enzymes (five, three times a day on empty stomach), liver flush (once per month), and coffee enemas.

“Peace begins with each of us taking care of our bodies and minds every day.” – Thich Nhat Hanh.

New Perspectives on Salicinium for Integrative Cancer Treatment

Virginia Von Schaefer, MD, discusses the rationale for using Salicinium as an integrative cancer treatment.

Cancer incidence has been accelerated by post WWII hydrocarbon toxicity created by extensive use of chemicals in food sources, water, clothing, plastics, pesticides and heavy metals.  Polypharmacy causes (all drugs, too many drugs) “Magic Pill” obsession.  Electromagnetic fields, nuclear radiation, ionizing radiation and EMFs all enhance cancer formation. In addition, chronic/sub-acute infections from bacteria, viruses, parasites, fungi, and candida all make energy via anaerobic fermentation metabolism and contribute to creating microenvironment conducive to cancer cell growth.

Stress is another contributor. It arises in response to forces either within us or in our environment that are beyond our control and triggers a “fight or flight” syndrome. It increases chronic levels of blood glucose, sympathetic nervous system overdrive, decreases parasympathetic driven functions of regrowth and repair, as well as decreasing oxygen tension.

The challenges are greater now than ever before because cancer is pandemic. In the USA estimates are that 50% of males and 41-45% of females will develop cancer in their lifetimes.  Worldwide these numbers are growing daily.  Treatment results are abysmal with no significant increase in five-year survival over the past 50 years using the current mainstay of treatment with surgery, chemotherapy and radiation therapy.

What are we missing?  How can we overcome seemingly insurmountable odds?  Dr. Von Schaefer’s focus is to treat the whole person and apply principles of biochemistry and cell biology to medical problem solving.

She revisits Otto Warburg’s phenomenon of cancer cells being anerobic, utilizing fermentation.  Fermentation metabolism involves a neutral pH (7.0) and extrudes lactate.  Leaky membranes cause a loss of electrochemical gradient across the membrane, and when “leaky” the delicate electron transport chain of the mitochondria fails.  Warburg concluded that cancer is a disease of mitochondrial dysfunction promoted by environmental hydrocarbon toxicity.

Cancer tissue also has upregulated glucose receptors +GLUT-4 and excess iron (400 x the amount of iron needed for DNA replication).  Increased extracellular acidity increases angiogenesis, fibrin coating, and nagalase, which blocks GcMAF activation.

Trophoblast cells come from the fetus, not the mother. They cause arterial remodeling to attach cells to the maternal spiral arteries, invade and remodel them to create adequate blood supply to the fetus.  The trophoblast causes phagocyte repulsion, masking them from maternal lymphocytes.  This masking is affected by the release of “fibrinoid sialomucin,” which was demonstrated to be nagalase.  (Simon & Russel 1962:  Carrie & Bagshawe, 1967/ Peter W. Stackpoole, 1971, Trophoblastic Nature of Cancer )

Nagalase (alpha-N-acetylgalactosaminidase) creates a protective fibrin coat on cancer cells and repels phagocytes. It blocks vitamin D binding protein complex (GcMAF), which is required to activate tissue macrophages. Elevated nagalase indicates increased tumor activity and possibly indicates aggressiveness of the tumor. Serial monitoring can tell the progression of therapy.

When cancer cells are deprived of energy and cannot perform functions to maintain protective microenvironment, decreasing nagalase leads to reduction of the fibrin coat, reduces angiogenesis, and increases effective GcMAF.  Thus, cancer cells are starved, de-cloaked, and vulnerable to the immune system.

Salicinium targets cells conducting fermentation/anaerobic respiration. It saturates tissue especially in areas of pleural space, peritoneal cavity, crosses the blood-brain barrier and changes abnormal cellular microenvironment that protect the cancer cell via blocking nagalase release, acid extrusion, angiogenesis, fibrin coating, and deactivation of GcMAF. The Salicinium blocks progression of glycolysis to produce 4 ATP/net2 ATP and blocks acid extrusion/lactic acid formation.

Salicinium contains a benzaldehyde ring. The glucoside/complex glycome of 4-hydroxy-benzaldehyde is extracted from the plant Helicia nilagirica.  In the early 1970s, the Japanese researched and demonstrated the anti-tumor effect of benzaldehyde via several different mechanisms. It causes disruption of cytosol glycolysis and increases NK cell activity.  Benzaldehyde reduces phosphorylation of a class of “HUB” signaling proteins.

When using Salicinium, the following need to be avoided: oxidative therapies, ozone, H202, artemisinin, genistein, SOD, IP6, MMS, cell food, and high-dose vitamin C. Compatible therapies include glutathione, Meyers cocktail, HBOT, EDTA, IPT/APT and ERT.  Synergistic therapeutics include mistletoe, hyperthermia, sound therapy, and gallium maltolate. Dr. Von Schaefer presented seven cases of positive response from Salicinium treatment in conjunction with other modalities.

Von Schaefer reminded attendees that the therapeutic demise of cancer cells with Salicinium may be proceeded by their expansion. Meningeal metastases may expand during treatment and cause optic nerve damage.  Liver tumors may expand and cause obstruction.  Pancreatic tumors may expand and cause duct obstruction.

This ends a very great meeting presented by Annie Brandt. These 28 speakers offered state-of-the-art integrative cancer therapies and increased our repertoire of responses to this plague.